These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 2480605)
21. Construction and enhanced cytotoxicity of a [cyanovirin-N]-[Pseudomonas exotoxin] conjugate against human immunodeficiency virus-infected cells. Mori T; Shoemaker RH; McMahon JB; Gulakowski RJ; Gustafson KR; Boyd MR Biochem Biophys Res Commun; 1997 Oct; 239(3):884-8. PubMed ID: 9367864 [TBL] [Abstract][Full Text] [Related]
22. Failure of short-term CD4-PE40 infusions to reduce virus load in human immunodeficiency virus-infected persons. Ramachandran RV; Katzenstein DA; Wood R; Batts DH; Merigan TC J Infect Dis; 1994 Oct; 170(4):1009-13. PubMed ID: 7930696 [TBL] [Abstract][Full Text] [Related]
23. Specific killing of HIV-infected lymphocytes by a recombinant immunotoxin directed against the HIV-1 envelope glycoprotein. Bera TK; Kennedy PE; Berger EA; Barbas CF; Pastan I Mol Med; 1998 Jun; 4(6):384-91. PubMed ID: 10780881 [TBL] [Abstract][Full Text] [Related]
24. The block to HIV-1 envelope glycoprotein-mediated membrane fusion in animal cells expressing human CD4 can be overcome by a human cell component(s). Broder CC; Dimitrov DS; Blumenthal R; Berger EA Virology; 1993 Mar; 193(1):483-91. PubMed ID: 8438583 [TBL] [Abstract][Full Text] [Related]
25. Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds. Madani N; Princiotto AM; Zhao C; Jahanbakhshsefidi F; Mertens M; Herschhorn A; Melillo B; Smith AB; Sodroski J J Virol; 2017 Feb; 91(3):. PubMed ID: 27881646 [TBL] [Abstract][Full Text] [Related]
26. Inhibition of HIV and SIV infectivity by blockade of alpha-glucosidase activity. Ratner L; vander Heyden N; Dedera D Virology; 1991 Mar; 181(1):180-92. PubMed ID: 1704656 [TBL] [Abstract][Full Text] [Related]
27. Binding of soluble CD4 proteins to human immunodeficiency virus type 1 and infected cells induces release of envelope glycoprotein gp120. Hart TK; Kirsh R; Ellens H; Sweet RW; Lambert DM; Petteway SR; Leary J; Bugelski PJ Proc Natl Acad Sci U S A; 1991 Mar; 88(6):2189-93. PubMed ID: 2006155 [TBL] [Abstract][Full Text] [Related]
28. The env protein of an infectious noncytopathic HIV-2 is deficient in syncytium formation. Mulligan MJ; Kumar P; Hui HX; Owens RJ; Ritter GD; Hahn BH; Compans RW AIDS Res Hum Retroviruses; 1990 Jun; 6(6):707-20. PubMed ID: 2364016 [TBL] [Abstract][Full Text] [Related]
29. Primary HIV-1 isolates refractory to neutralization by soluble CD4 are potently inhibited by CD4-Pseudomonas exotoxin. Kennedy PE; Moss B; Berger EA Virology; 1993 Jan; 192(1):375-9. PubMed ID: 8517027 [TBL] [Abstract][Full Text] [Related]
30. A human immunodeficiency virus-transgenic mouse model for assessing interventions that block microbial-induced proviral expression. Schito ML; Kennedy PE; Kowal RP; Berger EA; Sher A J Infect Dis; 2001 Jun; 183(11):1592-600. PubMed ID: 11343207 [TBL] [Abstract][Full Text] [Related]
31. Mechanism of anti-human immunodeficiency virus action of polyoxometalates, a class of broad-spectrum antiviral agents. Yamamoto N; Schols D; De Clercq E; Debyser Z; Pauwels R; Balzarini J; Nakashima H; Baba M; Hosoya M; Snoeck R Mol Pharmacol; 1992 Dec; 42(6):1109-17. PubMed ID: 1282664 [TBL] [Abstract][Full Text] [Related]
33. A rapid solution immunoassay to quantify binding of the human immunodeficiency virus envelope glycoprotein to soluble CD4. McQuade TJ; Pitts TW; Tarpley WG Biochem Biophys Res Commun; 1989 Aug; 163(1):172-6. PubMed ID: 2549987 [TBL] [Abstract][Full Text] [Related]
34. Insertion of constant region domains of human IgG1 into CD4-PE40 increases its plasma half-life. Batra JK; Kasturi S; Gallo MG; Voorman RL; Maio SM; Chaudhary VK; Pastan I Mol Immunol; 1993 Mar; 30(4):379-86. PubMed ID: 8455638 [TBL] [Abstract][Full Text] [Related]
35. Identification of Human Anti-HIV gp160 Monoclonal Antibodies That Make Effective Immunotoxins. Pincus SH; Song K; Maresh GA; Hamer DH; Dimitrov DS; Chen W; Zhang MY; Ghetie VF; Chan-Hui PY; Robinson JE; Vitetta ES J Virol; 2017 Feb; 91(3):. PubMed ID: 27852851 [TBL] [Abstract][Full Text] [Related]
36. Envelope glycoproteins from biologically diverse isolates of immunodeficiency viruses have widely different affinities for CD4. Ivey-Hoyle M; Culp JS; Chaikin MA; Hellmig BD; Matthews TJ; Sweet RW; Rosenberg M Proc Natl Acad Sci U S A; 1991 Jan; 88(2):512-6. PubMed ID: 1899141 [TBL] [Abstract][Full Text] [Related]
37. HIV envelope glycoprotein-induced cell killing by apoptosis is enhanced with increased expression of CD26 in CD4+ T cells. Jacotot E; Callebaut C; Blanco J; Rivière Y; Krust B; Hovanessian AG Virology; 1996 Sep; 223(2):318-30. PubMed ID: 8806567 [TBL] [Abstract][Full Text] [Related]
38. Lineage-Specific Differences between the gp120 Inner Domain Layer 3 of Human Immunodeficiency Virus and That of Simian Immunodeficiency Virus. Ding S; Medjahed H; Prévost J; Coutu M; Xiang SH; Finzi A J Virol; 2016 Nov; 90(22):10065-10073. PubMed ID: 27535053 [TBL] [Abstract][Full Text] [Related]
39. Cyanovirin-N, a potent human immunodeficiency virus-inactivating protein, blocks both CD4-dependent and CD4-independent binding of soluble gp120 (sgp120) to target cells, inhibits sCD4-induced binding of sgp120 to cell-associated CXCR4, and dissociates bound sgp120 from target cells. Mori T; Boyd MR Antimicrob Agents Chemother; 2001 Mar; 45(3):664-72. PubMed ID: 11181340 [TBL] [Abstract][Full Text] [Related]
40. Characterization of siamycin I, a human immunodeficiency virus fusion inhibitor. Lin PF; Samanta H; Bechtold CM; Deminie CA; Patick AK; Alam M; Riccardi K; Rose RE; White RJ; Colonno RJ Antimicrob Agents Chemother; 1996 Jan; 40(1):133-8. PubMed ID: 8787894 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]